Mass Tort brief
Labeling Claims and Litigation Overhangs
Central-Lod District Court advances Golda class action while Teva secures investment-grade rating as opioid liabilities clear.
Mass Tort
District court certification of Golda's $116M class action puts retail food chains on notice — mislabeling sugar-free products creates massive financial liability in Israeli courts.
BackgroundIsraeli consumer protection laws strictly regulate food labeling disclosures, capping sugar-free designation at 0.5 grams per 100 grams of product. Class-action litigation in Israel provides a primary mechanism for challenging corporate labeling misrepresentations.
- Laboratory tests submitted to court showed up to 6.6 grams of lactose per 100 grams — 13 times the statutory limit for sugar-free claims.
- Judge Iris Rabinovich-Baron rejected defense arguments that consumers naturally assume milk products contain lactose, certifying the plaintiff class.
- The lawsuit seeks financial compensation for consumers who bought falsely labeled products over a multi-year retail operational window.
Mass Tort
Teva's motion in limine reveals how Middle East geopolitical conflict spills into US courtroom strategy — corporate defense teams are taking preemptive action against potential jury bias.
BackgroundTeva is defending against antitrust multidistrict litigation brought by US health insurers alleging market allocation on generic medications. Corporate defendants routinely file motions in limine to exclude potentially prejudicial nationality arguments from jury trials.
- Teva's legal team argued that national origin references are irrelevant to whether price-fixing occurred on generic medications like baclofen.
- The motion highlights how geopolitical tensions in the Middle East create complex jury bias risks for multinational Israeli corporations in foreign courts.
- The presiding federal judge is expected to issue an evidentiary ruling ahead of jury selection later this month.
Mass Tort
Teva has overcome its mass-tort credit overhang — returning to investment grade lowers borrowing costs and solidifies its long-term balance sheet recovery.
BackgroundTeva Pharmaceutical spent years burdened by junk credit ratings due to billions in nationwide US opioid settlement liabilities. The Israeli drugmaker's 'Pivot to Growth' strategy has prioritized debt paydowns alongside commercial launch of branded biopharmaceuticals.
- Moody's projected Teva will generate approximately $2.0 billion in free cash flow over the next 12 months to cover settlement installments.
- The upgrade follows a similar rating increase by Fitch Ratings, restoring full access to investment-grade corporate bond markets.
- CFO Eli Kalif noted the rating recovery significantly lowers interest expenses as Teva refinances maturing debt tranches.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
